Expert Interview
Digging into the recent Phase 2 Cohort 5 results of Bridgebio's ifigratinib in achondroplasia
Ticker(s): BBIO, BMRN, ASNDInstitution: Hôpital Femme-Mère-Enfant
- Professor of Pediatrics and Head of the Division of Pediatric Endocrinology at Hôpital Femme-Mère-Enfant (Lyon, France)
- Treats ~12 patients with achondroplasia.
- Research focuses on a variety of endocrinological conditions in children and was a co-author on the PROPEL studies of Infigratinib in Children with Achondroplasia.
Please describe your clinical practice, in particular with treating achondroplasia patients, and research in the space.
Added By: max_adminHow many patients do you treat with achondroplasia? What treatment options do they have?
Added By: max_adminWhat is the mechanism of action of a C-type natriuretic peptide like vosoritide, how does it regulate bone growth?
Added By: max_adminChange from baseline in growth velocity after one year of treatment with vosoritide, the primary endpoint, was 1.6 cm/yr. How satisfactory is this result?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
